Cat. No.: HY-10224

Panobinostat

(Synonyms: LBH589; NVP-LBH589)

89 Cited Publications

Avis client

Based on 89 publication(s) in Google Scholar

Panobinostat (LBH589; NVP-LBH589) is a potent and orally active non-selective HDAC inhibitor, and has antineoplastic activities. Panobinostat induces HIV-1 virus production even at low concentration range 8-31 nM, stimulates HIV-1 expression in latently infected cells. Panobinostat induces cell apoptosis and autophagy. Panobinostat can be used for the study of refractory or relapsed multiple myeloma.

Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.

Pureté: 99.37%
CAS No.: 404950-80-7
Formule: C₂₁H₂₃N₃O₂
Masse moléculaire:349.43

Stockage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 1 year , -20°C, 6 months

Panobinostat Chemical Structure

CAS No.: 404950-80-7

Size

Prix

Stock

Quantité

Amount: USD 0.00

* Veuillez sélectionner la quantité avant d'ajouter des articles.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Activité biologique
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
- Essai clinique
Chemical Information
Publications (89)
Solvant et solubilité
- In Vitro
- In Vivo
Protocole
Pureté et documentation
Références
Help & FAQs
Classifications
Bioz

Activité biologique

Description

Panobinostat (LBH589; NVP-LBH589) is a potent and orally active non-selective HDAC inhibitor, and has antineoplastic activities^[1]^[2]. Panobinostat induces HIV-1 virus production even at low concentration range 8-31 nM, stimulates HIV-1 expression in latently infected cells^[4]. Panobinostat induces cell apoptosis and autophagy. Panobinostat can be used for the study of refractory or relapsed multiple myeloma^[3].

IC₅₀ & Target^[1]^[5]

HDAC

HIV-1

Voir tous les produits spécifiques à Isoform HDAC :

Voir tous les produits spécifiques à Isoform HIV :

Cellular Effect

Cell Line	Type	Value	Description	References
A2780	IC₅₀	0.035 μM Compound: LBH589	Antiproliferative activity against human A2780 cells after 96 hrs by celltiter 96 assay Antiproliferative activity against human A2780 cells after 96 hrs by celltiter 96 assay	[PMID: 21634430]
A2780	EC₅₀	150.71 nM Compound: LBH-589	Inhibition of HDAC6 in human A2780S cells assessed as tubulin acetylation incubated for 6 hrs by cytoblot assay Inhibition of HDAC6 in human A2780S cells assessed as tubulin acetylation incubated for 6 hrs by cytoblot assay	[PMID: 27186676]
A2780	EC₅₀	169.5 nM Compound: LBH-589	Inhibition of HDAC1/2/3 in human A2780S cells assessed as histone H3 acetylation incubated for 6 hrs by cytoblot assay Inhibition of HDAC1/2/3 in human A2780S cells assessed as histone H3 acetylation incubated for 6 hrs by cytoblot assay	[PMID: 27186676]
A2780	IC₅₀	8.32 nM Compound: LBH-589	Cytotoxicity against human A2780S cells assessed as growth inhibition after 24 hrs by MTT assay Cytotoxicity against human A2780S cells assessed as growth inhibition after 24 hrs by MTT assay	[PMID: 27186676]
A2780	IC₅₀	54.8 nM Compound: Panobinostat	Antiproliferative activity against human A2780 cells after 72 hrs by microplate reader based MTT assay Antiproliferative activity against human A2780 cells after 72 hrs by microplate reader based MTT assay	[PMID: 31431326]
A2780	IC₅₀	7.67 nM Compound: Panobinostat	Inhibition of HDAC in human A2780 cells using Boc-Lys(epsilon-Ac)-AMC as substrate preincubated for 18 hrs followed by substrate addition and further incubation for 3 hrs by microplate reader based fluorescence assay Inhibition of HDAC in human A2780 cells using Boc-Lys(epsilon-Ac)-AMC as substrate preincubated for 18 hrs followed by substrate addition and further incubation for 3 hrs by microplate reader based fluorescence assay	[PMID: 31431326]
A549	IC₅₀	0.02 μM Compound: Panobinostat	Antiproliferative activity against human A549 cells measured after 72 hrs by CCK8 assay Antiproliferative activity against human A549 cells measured after 72 hrs by CCK8 assay	[PMID: 31272794]
B16	GI₅₀	0.15 μM Compound: LBH589	Growth inhibition of mouse B16 cells incubated for 48 hrs by MTT assay Growth inhibition of mouse B16 cells incubated for 48 hrs by MTT assay	[PMID: 23009203]
Bel-7402	IC₅₀	21.28 nM Compound: LBH589	Antiproliferative activity against human Bel7402 cells assessed as reduction in cell growth after 72 hrs Antiproliferative activity against human Bel7402 cells assessed as reduction in cell growth after 72 hrs	[PMID: 31855601]
CAL-148	IC₅₀	<0.1 μM Compound: Panobinostat	Antiproliferative activity against human CAL148 cells measured after 72 hrs by CCK8 assay Antiproliferative activity against human CAL148 cells measured after 72 hrs by CCK8 assay	[PMID: 31272794]
CAL-27	IC₅₀	10.9 nM Compound: Panobinostat	Antiproliferative activity against human CAL27 cells after 72 hrs by microplate reader based MTT assay Antiproliferative activity against human CAL27 cells after 72 hrs by microplate reader based MTT assay	[PMID: 31431326]
COLO 205	IC₅₀	0.018 μM Compound: LBH589	Antiproliferative activity against human COLO205 cells after 96 hrs by celltiter 96 assay Antiproliferative activity against human COLO205 cells after 96 hrs by celltiter 96 assay	[PMID: 21634430]
EBC-1	IC₅₀	27.85 nM Compound: LBH589	Antiproliferative activity against human EBC1 cells assessed as reduction in cell growth after 72 hrs Antiproliferative activity against human EBC1 cells assessed as reduction in cell growth after 72 hrs	[PMID: 31855601]
HCT-116	IC₅₀	0.048 μM Compound: LBH589	Antiproliferative activity against human HCT116 cells after 96 hrs by celltiter 96 assay Antiproliferative activity against human HCT116 cells after 96 hrs by celltiter 96 assay	[PMID: 21634430]
HCT-116	IC₅₀	3.36 nM Compound: LBH-589	Cytotoxicity against human HCT116 cells assessed as growth inhibition after 24 hrs by MTT assay Cytotoxicity against human HCT116 cells assessed as growth inhibition after 24 hrs by MTT assay	[PMID: 27186676]
HEK293	IC₅₀	11 nM Compound: LBH589	Inhibition of HDAC6 (unknown origin) expressed in HEK293 cells using [3H]acetylated human histone H4 peptide as substrate by scintillation counting Inhibition of HDAC6 (unknown origin) expressed in HEK293 cells using [3H]acetylated human histone H4 peptide as substrate by scintillation counting	[PMID: 22344701]
HEK293	IC₅₀	2.1 nM Compound: LBH589	Inhibition of HDAC3 (unknown origin) expressed in HEK293 cells using [3H]acetylated human histone H4 peptide as substrate by scintillation counting Inhibition of HDAC3 (unknown origin) expressed in HEK293 cells using [3H]acetylated human histone H4 peptide as substrate by scintillation counting	[PMID: 22344701]
HEK293	IC₅₀	2.5 nM Compound: LBH589	Inhibition of HDAC1 (unknown origin) expressed in HEK293 cells using [3H]acetylated human histone H4 peptide as substrate by scintillation counting Inhibition of HDAC1 (unknown origin) expressed in HEK293 cells using [3H]acetylated human histone H4 peptide as substrate by scintillation counting	[PMID: 22344701]
HEK293	IC₅₀	200 nM Compound: LBH589	Inhibition of HDAC4 (unknown origin) expressed in HEK293 cells using [3H]acetylated human histone H4 peptide as substrate by scintillation counting Inhibition of HDAC4 (unknown origin) expressed in HEK293 cells using [3H]acetylated human histone H4 peptide as substrate by scintillation counting	[PMID: 22344701]
HEK293	IC₅₀	0.07 μM Compound: 34	Cytotoxicity against HEK293 cells after 48 hrs by resazurin assay Cytotoxicity against HEK293 cells after 48 hrs by resazurin assay	[PMID: 28241112]
HEK293	IC₅₀	70 nM Compound: Panobinostat	Cytotoxicity against HEK293 cells after 48 hrs by resazurin dye based assay Cytotoxicity against HEK293 cells after 48 hrs by resazurin dye based assay	[PMID: 30245402]
HEK293	CC₅₀	0.028 μM Compound: Panobinostat	Cytotoxicity against HEK293 cells assessed as reduction in cell growth incubated for 48 hrs by MTS assay Cytotoxicity against HEK293 cells assessed as reduction in cell growth incubated for 48 hrs by MTS assay	[PMID: 30973727]
HeLa	IC₅₀	30 nM Compound: LBH589	Inhibition of HDAC in human HeLa cells using Fluor de Lys as substrate by fluorescence assay Inhibition of HDAC in human HeLa cells using Fluor de Lys as substrate by fluorescence assay	[PMID: 23639537]
HeLa	IC₅₀	0.83 nM Compound: LBH-589	Inhibition of HDAC in human HeLa cell nuclear extract using Ac-Leu-Gly-Lys (Ac)-AMC as substrate after 30 mins by fluorescence assay Inhibition of HDAC in human HeLa cell nuclear extract using Ac-Leu-Gly-Lys (Ac)-AMC as substrate after 30 mins by fluorescence assay	[PMID: 27186676]
HeLa	IC₅₀	22 nM Compound: LBH589	Inhibition Class 1 histone deacetylase in human HeLa nuclear extracts using Fluor-de- Lys-green substrate by fluorescence assay Inhibition Class 1 histone deacetylase in human HeLa nuclear extracts using Fluor-de- Lys-green substrate by fluorescence assay	[PMID: 31400937]
HepG2	CC₅₀	<0.078 μM Compound: Panobinostat	Cytotoxicity against human HepG2 cells assessed as reduction in cell growth incubated for 48 hrs by CellTiter-Glo assay Cytotoxicity against human HepG2 cells assessed as reduction in cell growth incubated for 48 hrs by CellTiter-Glo assay	[PMID: 30973727]
HepG2	IC₅₀	<0.1 μM Compound: Panobinostat	Antiproliferative activity against human HepG2 cells measured after 72 hrs by CCK8 assay Antiproliferative activity against human HepG2 cells measured after 72 hrs by CCK8 assay	[PMID: 31272794]
HT-29	IC₅₀	37.55 nM Compound: LBH589	Antiproliferative activity against human HT-29 cells assessed as reduction in cell growth after 72 hrs Antiproliferative activity against human HT-29 cells assessed as reduction in cell growth after 72 hrs	[PMID: 31855601]
Huh-7	CC₅₀	0.0035 μM Compound: 8, LBH589	Cytotoxicity against human HuH7 cells assessed as inhibition of cell viability after 3 days by CellTiter 96 assay Cytotoxicity against human HuH7 cells assessed as inhibition of cell viability after 3 days by CellTiter 96 assay	[PMID: 25490700]
HuT78	EC₅₀	4.3 nM Compound: 2	Pro-apoptotic activity in human HUT78 cells after 18 hrs by caspase-Glo 3/7 assay Pro-apoptotic activity in human HUT78 cells after 18 hrs by caspase-Glo 3/7 assay	[PMID: 30122227]
KM3/BTZ	IC₅₀	150 nM Compound: LBH-589	Antiproliferative activity against bortezomib resistant human KM3/BTZ cells incubated for 48 hrs by MTT assay Antiproliferative activity against bortezomib resistant human KM3/BTZ cells incubated for 48 hrs by MTT assay	[PMID: 32267687]
KM3/BTZ	IC₅₀	20.1 nM Compound: LBH-589	Antiproliferative activity against bortezomib resistant human KM3/BTZ cells in presence of bortezomib incubated for 48 hrs by MTT assay Antiproliferative activity against bortezomib resistant human KM3/BTZ cells in presence of bortezomib incubated for 48 hrs by MTT assay	[PMID: 32267687]
MCF7	IC₅₀	9 nM Compound: LBH589	Antiproliferative activity against human MCF7 cells assessed as reduction in cell growth after 72 hrs Antiproliferative activity against human MCF7 cells assessed as reduction in cell growth after 72 hrs	[PMID: 31855601]
MDA-MB-231	IC₅₀	29.13 nM Compound: LBH589	Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell growth after 72 hrs Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell growth after 72 hrs	[PMID: 31855601]
MM1.S	GI₅₀	8.9 nM Compound: 2	Antiproliferative activity against human MM1.S cells assessed as inhibition of cell proliferation measured up to 72 hrs by CellTiter96 Aqueous one reagent based assay Antiproliferative activity against human MM1.S cells assessed as inhibition of cell proliferation measured up to 72 hrs by CellTiter96 Aqueous one reagent based assay	[PMID: 33661013]
MV4-11	IC₅₀	2.97 nM Compound: LBH-589	Cytotoxicity against human MV4-11 cells assessed as growth inhibition after 24 hrs by MTT assay Cytotoxicity against human MV4-11 cells assessed as growth inhibition after 24 hrs by MTT assay	[PMID: 27186676]
MV4-11	EC₅₀	<30 nM Compound: Panobinostat	Cytotoxicity against human MV4-11 cells assessed as reduction in cell viability incubated for 48 hrs by Cell-titer-blue cell viability assay Cytotoxicity against human MV4-11 cells assessed as reduction in cell viability incubated for 48 hrs by Cell-titer-blue cell viability assay	[PMID: 27754681]
MV4-11	EC₅₀	5.2 nM Compound: Pan; LBH589	Antiproliferative activity against human MV4-11 cells assessed as reduction in cell viability after 48 hrs by CellTiter-Blue dye based spectrophotometric analysis Antiproliferative activity against human MV4-11 cells assessed as reduction in cell viability after 48 hrs by CellTiter-Blue dye based spectrophotometric analysis	[PMID: 32321249]
NCI-H1975	IC₅₀	17.51 nM Compound: LBH589	Antiproliferative activity against human NCI-H1975 cells assessed as reduction in cell growth after 72 hrs Antiproliferative activity against human NCI-H1975 cells assessed as reduction in cell growth after 72 hrs	[PMID: 31855601]
NCI-N87	IC₅₀	8.42 nM Compound: LBH589	Antiproliferative activity against human NCI-N87 cells assessed as reduction in cell growth after 72 hrs Antiproliferative activity against human NCI-N87 cells assessed as reduction in cell growth after 72 hrs	[PMID: 31855601]
NFF	IC₅₀	0.07 μM Compound: 34	Cytotoxicity against human NFF cells after 72 hrs by SRB assay Cytotoxicity against human NFF cells after 72 hrs by SRB assay	[PMID: 28241112]
NFF	IC₅₀	70 nM Compound: Panobinostat	Cytotoxicity against human NFF cells after 72 hrs by sulforhodamine B assay Cytotoxicity against human NFF cells after 72 hrs by sulforhodamine B assay	[PMID: 30245402]
NFF	IC₅₀	0.07 μM Compound: Panobinostat	Cytotoxicity against human NFF cells incubated for 72 hrs by SRB assay Cytotoxicity against human NFF cells incubated for 72 hrs by SRB assay	[PMID: 39208744]
NSC	IC₅₀	0.08 μM Compound: Chemical Probe: Panobinostat	Cytotoxicity against human fetal NSC assessed as reduction in cell vaibility incubated for 48 hrs by alamar blue assay Cytotoxicity against human fetal NSC assessed as reduction in cell vaibility incubated for 48 hrs by alamar blue assay	[PMID: 30559935]
PANC-1	IC₅₀	1 μM Compound: Panobinostat	Cytotoxicity against human PANC1 cells assessed as reduction in cell viability incubated upto 72 hrs by MTT assay Cytotoxicity against human PANC1 cells assessed as reduction in cell viability incubated upto 72 hrs by MTT assay	[PMID: 33951490]
PC-3	IC₅₀	0.024 μM Compound: LBH589	Antiproliferative activity against human PC3 cells after 96 hrs by celltiter 96 assay Antiproliferative activity against human PC3 cells after 96 hrs by celltiter 96 assay	[PMID: 21634430]
S2	IC₅₀	1.8 nM Compound: 5, LBH-589	Inhibition of Plasmodium falciparum HDAC1 expressed in Drosophila melanogaster S2 cells Inhibition of Plasmodium falciparum HDAC1 expressed in Drosophila melanogaster S2 cells	[PMID: 19317450]
Sf21	IC₅₀	13 nM Compound: LBH589	Inhibition of flag-tagged HDAC2 (unknown origin) expressed in SF21 cells using [3H]acetylated human histone H4 peptide as substrate by scintillation counting Inhibition of flag-tagged HDAC2 (unknown origin) expressed in SF21 cells using [3H]acetylated human histone H4 peptide as substrate by scintillation counting	[PMID: 22344701]
Sf9	IC₅₀	280 nM Compound: LBH589	Inhibition of his-strep-tagged HDAC8 (unknown origin) expressed in SF9 cells using [3H]acetylated human histone H4 peptide as substrate by scintillation counting Inhibition of his-strep-tagged HDAC8 (unknown origin) expressed in SF9 cells using [3H]acetylated human histone H4 peptide as substrate by scintillation counting	[PMID: 22344701]
Sf9	IC₅₀	>10000 nM Compound: LBH-589	Inhibition of recombinant human p110beta expressed in baculovirus infected insect Sf9 cells incubated for 1 hr by ADP-gloreagen assay Inhibition of recombinant human p110beta expressed in baculovirus infected insect Sf9 cells incubated for 1 hr by ADP-gloreagen assay	[PMID: 27186676]
Sf9	IC₅₀	1.26 nM Compound: LBH-589	Inhibition of full length C-terminal His/FLAG-tagged human recombinant HDAC1 expressed in baculovirus infected insect Sf9 cells using Ac-peptide-AMC as substrate assessed as release of AMC preincubated for 15 mins followed by substrate addition measured a Inhibition of full length C-terminal His/FLAG-tagged human recombinant HDAC1 expressed in baculovirus infected insect Sf9 cells using Ac-peptide-AMC as substrate assessed as release of AMC preincubated for 15 mins followed by substrate addition measured a	[PMID: 27186676]
Sf9	IC₅₀	190.3 nM Compound: LBH-589	Inhibition of human recombinant HDAC5 expressed in baculovirus infected insect Sf9 cells using Ac-peptide-AMC as substrate assessed as release of AMC preincubated for 15 mins followed by substrate addition measured after 1 hr by fluorescence assay Inhibition of human recombinant HDAC5 expressed in baculovirus infected insect Sf9 cells using Ac-peptide-AMC as substrate assessed as release of AMC preincubated for 15 mins followed by substrate addition measured after 1 hr by fluorescence assay	[PMID: 27186676]
Sf9	IC₅₀	2.27 nM Compound: LBH-589	Inhibition of full length C-terminal His-tagged human recombinant HDAC3/NCOR2 (395 to 489 residues) expressed in baculovirus infected insect Sf9 cells using Ac-peptide-AMC as substrate assessed as release of AMC preincubated for 15 mins followed by substr Inhibition of full length C-terminal His-tagged human recombinant HDAC3/NCOR2 (395 to 489 residues) expressed in baculovirus infected insect Sf9 cells using Ac-peptide-AMC as substrate assessed as release of AMC preincubated for 15 mins followed by substr	[PMID: 27186676]
Sf9	IC₅₀	3.28 nM Compound: LBH-589	Inhibition of full length human recombinant HDAC2 expressed in baculovirus infected insect Sf9 cells using Ac-peptide-AMC as substrate assessed as release of AMC preincubated for 15 mins followed by substrate addition measured after 1 hr by fluorescence a Inhibition of full length human recombinant HDAC2 expressed in baculovirus infected insect Sf9 cells using Ac-peptide-AMC as substrate assessed as release of AMC preincubated for 15 mins followed by substrate addition measured after 1 hr by fluorescence a	[PMID: 27186676]
Sf9	IC₅₀	337.8 nM Compound: LBH-589	Inhibition of N-terminal GST/C-terminal His-tagged human recombinant HDAC4 (627 to 1084 residues) expressed in baculovirus infected insect Sf9 cells using Ac-peptide-AMC as substrate assessed as release of AMC preincubated for 15 mins followed by substrat Inhibition of N-terminal GST/C-terminal His-tagged human recombinant HDAC4 (627 to 1084 residues) expressed in baculovirus infected insect Sf9 cells using Ac-peptide-AMC as substrate assessed as release of AMC preincubated for 15 mins followed by substrat	[PMID: 27186676]
Sf9	IC₅₀	4.16 nM Compound: LBH-589	Inhibition of full length human recombinant HDAC6 expressed in baculovirus infected insect Sf9 cells using Ac-peptide-AMC as substrate assessed as release of AMC preincubated for 15 mins followed by substrate addition measured after 1 hr by fluorescence a Inhibition of full length human recombinant HDAC6 expressed in baculovirus infected insect Sf9 cells using Ac-peptide-AMC as substrate assessed as release of AMC preincubated for 15 mins followed by substrate addition measured after 1 hr by fluorescence a	[PMID: 27186676]
Sf9	IC₅₀	4.45 nM Compound: LBH-589	Inhibition of human recombinant HDAC10 expressed in baculovirus infected insect Sf9 cells using Ac-peptide-AMC as substrate assessed as release of AMC preincubated for 15 mins followed by substrate addition measured after 1 hr by fluorescence assay Inhibition of human recombinant HDAC10 expressed in baculovirus infected insect Sf9 cells using Ac-peptide-AMC as substrate assessed as release of AMC preincubated for 15 mins followed by substrate addition measured after 1 hr by fluorescence assay	[PMID: 27186676]
Sf9	IC₅₀	4.86 nM Compound: LBH-589	Inhibition of full length C-terminal His-tagged human recombinant HDAC8 expressed in baculovirus infected insect Sf9 cells using Ac-peptide-AMC as substrate assessed as release of AMC preincubated for 15 mins followed by substrate addition measured after Inhibition of full length C-terminal His-tagged human recombinant HDAC8 expressed in baculovirus infected insect Sf9 cells using Ac-peptide-AMC as substrate assessed as release of AMC preincubated for 15 mins followed by substrate addition measured after	[PMID: 27186676]
Sf9	IC₅₀	4112 nM Compound: LBH-589	Inhibition of full length human recombinant HDAC11 expressed in baculovirus infected insect Sf9 cells using Ac-peptide-AMC as substrate assessed as release of AMC preincubated for 15 mins followed by substrate addition measured after 1 hr by fluorescence Inhibition of full length human recombinant HDAC11 expressed in baculovirus infected insect Sf9 cells using Ac-peptide-AMC as substrate assessed as release of AMC preincubated for 15 mins followed by substrate addition measured after 1 hr by fluorescence	[PMID: 27186676]
Sf9	IC₅₀	4354 nM Compound: LBH-589	Inhibition of N-terminal GST-tagged human recombinant HDAC7 (518 to end residues) expressed in baculovirus infected insect Sf9 cells using Ac-peptide-AMC as substrate assessed as release of AMC preincubated for 15 mins followed by substrate addition measu Inhibition of N-terminal GST-tagged human recombinant HDAC7 (518 to end residues) expressed in baculovirus infected insect Sf9 cells using Ac-peptide-AMC as substrate assessed as release of AMC preincubated for 15 mins followed by substrate addition measu	[PMID: 27186676]
Sf9	IC₅₀	887.8 nM Compound: LBH-589	Inhibition of C-terminal His-tagged human recombinant HDAC9 (604 to 1066 residues) expressed in baculovirus infected insect Sf9 cells using Ac-peptide-AMC as substrate assessed as release of AMC preincubated for 15 mins followed by substrate addition meas Inhibition of C-terminal His-tagged human recombinant HDAC9 (604 to 1066 residues) expressed in baculovirus infected insect Sf9 cells using Ac-peptide-AMC as substrate assessed as release of AMC preincubated for 15 mins followed by substrate addition meas	[PMID: 27186676]
Sf9	IC₅₀	>10000 nM Compound: LBH-589	Inhibition of N-terminal His6-tagged recombinant full-length human p110delta/untagged recombinant full length human p85alpha expressed in baculovirus infected insect Sf9 cells incubated for 2 hrs by kinase-glo assay Inhibition of N-terminal His6-tagged recombinant full-length human p110delta/untagged recombinant full length human p85alpha expressed in baculovirus infected insect Sf9 cells incubated for 2 hrs by kinase-glo assay	[PMID: 27186676]
Sf9	IC₅₀	0.001 μM Compound: LBH-589	Inhibition of C-terminal His-tagged and C-terminal FLAG-tagged full length human recombinant HDAC1 expressed in baculovirus coexpressed in fall armyworm Sf9 cells using carboxyfluorescein (FAM)-labeled acetylated/ trifluoroacetylated peptide as substrate Inhibition of C-terminal His-tagged and C-terminal FLAG-tagged full length human recombinant HDAC1 expressed in baculovirus coexpressed in fall armyworm Sf9 cells using carboxyfluorescein (FAM)-labeled acetylated/ trifluoroacetylated peptide as substrate	[PMID: 27377864]
Sf9	IC₅₀	0.002 μM Compound: LBH-589	Inhibition full length human recombinant HDAC2 expressed in baculovirus coexpressed in fall armyworm Sf9 cells using carboxyfluorescein (FAM)-labeled acetylated/ trifluoroacetylated peptide as substrate after 60 mins by fluorescence assay Inhibition full length human recombinant HDAC2 expressed in baculovirus coexpressed in fall armyworm Sf9 cells using carboxyfluorescein (FAM)-labeled acetylated/ trifluoroacetylated peptide as substrate after 60 mins by fluorescence assay	[PMID: 27377864]
Sf9	IC₅₀	0.002 μM Compound: LBH-589	Inhibition of human recombinant HDAC6 expressed in baculovirus coexpressed in fall armyworm Sf9 cells using carboxyfluorescein (FAM)-labeled acetylated/ trifluoroacetylated peptide as substrate after 60 mins by fluorescence assay Inhibition of human recombinant HDAC6 expressed in baculovirus coexpressed in fall armyworm Sf9 cells using carboxyfluorescein (FAM)-labeled acetylated/ trifluoroacetylated peptide as substrate after 60 mins by fluorescence assay	[PMID: 27377864]
Sf9	IC₅₀	0.092 μM Compound: LBH-589	Inhibition of N-terminal GST-tagged full length human recombinant HDAC5 expressed in baculovirus coexpressed in fall armyworm Sf9 cells using carboxyfluorescein (FAM)-labeled acetylated/ trifluoroacetylated peptide as substrate after 60 mins by fluorescen Inhibition of N-terminal GST-tagged full length human recombinant HDAC5 expressed in baculovirus coexpressed in fall armyworm Sf9 cells using carboxyfluorescein (FAM)-labeled acetylated/ trifluoroacetylated peptide as substrate after 60 mins by fluorescen	[PMID: 27377864]
Sf9	IC₅₀	0.231 μM Compound: LBH-589	Inhibition of C-terminal His-tagged full length human recombinant HDAC8 expressed in baculovirus coexpressed in fall armyworm Sf9 cells using carboxyfluorescein (FAM)-labeled acetylated/ trifluoroacetylated peptide as substrate after 60 mins by fluorescen Inhibition of C-terminal His-tagged full length human recombinant HDAC8 expressed in baculovirus coexpressed in fall armyworm Sf9 cells using carboxyfluorescein (FAM)-labeled acetylated/ trifluoroacetylated peptide as substrate after 60 mins by fluorescen	[PMID: 27377864]
Sf9	IC₅₀	0.373 μM Compound: LBH-589	Inhibition of N-terminal GST-tagged and C-terminal His-tagged human recombinant HDAC4 (627 to 1084 residues ) expressed in baculovirus coexpressed in fall armyworm Sf9 cells using carboxyfluorescein (FAM)-labeled acetylated/ trifluoroacetylated peptide as Inhibition of N-terminal GST-tagged and C-terminal His-tagged human recombinant HDAC4 (627 to 1084 residues ) expressed in baculovirus coexpressed in fall armyworm Sf9 cells using carboxyfluorescein (FAM)-labeled acetylated/ trifluoroacetylated peptide as	[PMID: 27377864]
Sf9	IC₅₀	2.68 μM Compound: LBH-589	Inhibition of C-terminal His-tagged human recombinant HDAC9 (604 to 1066 residues) expressed in baculovirus coexpressed in fall armyworm Sf9 cells using carboxyfluorescein (FAM)-labeled acetylated/ trifluoroacetylated peptide as substrate after 60 mins by Inhibition of C-terminal His-tagged human recombinant HDAC9 (604 to 1066 residues) expressed in baculovirus coexpressed in fall armyworm Sf9 cells using carboxyfluorescein (FAM)-labeled acetylated/ trifluoroacetylated peptide as substrate after 60 mins by	[PMID: 27377864]
Sf9	IC₅₀	2.83 μM Compound: LBH-589	Inhibition of N-terminal GST-tagged human recombinant HDAC7 (518 to end residues) expressed in baculovirus coexpressed in fall armyworm Sf9 cells using carboxyfluorescein (FAM)-labeled acetylated/ trifluoroacetylated peptide as substrate after 60 mins by Inhibition of N-terminal GST-tagged human recombinant HDAC7 (518 to end residues) expressed in baculovirus coexpressed in fall armyworm Sf9 cells using carboxyfluorescein (FAM)-labeled acetylated/ trifluoroacetylated peptide as substrate after 60 mins by	[PMID: 27377864]
Sf9	IC₅₀	>20000 nM Compound: LBH589	Inhibition of recombinant human C-terminal His-tagged HDAC9 (604 to 1066 residues) expressed in baculovirus infected Sf9 cells using Ac-Leu-Gly-Lys(Tfa)-AMC as substrate after 24 hrs by fluorescence based assay Inhibition of recombinant human C-terminal His-tagged HDAC9 (604 to 1066 residues) expressed in baculovirus infected Sf9 cells using Ac-Leu-Gly-Lys(Tfa)-AMC as substrate after 24 hrs by fluorescence based assay	[PMID: 31855601]
Sf9	IC₅₀	>20000 nM Compound: LBH589	Inhibition of recombinant N-terminal GST-tagged full length human HDAC5 expressed in baculovirus infected Sf9 cells using Ac-Leu-Gly-Lys(Tfa)-AMC as substrate after 24 hrs by fluorescence based assay Inhibition of recombinant N-terminal GST-tagged full length human HDAC5 expressed in baculovirus infected Sf9 cells using Ac-Leu-Gly-Lys(Tfa)-AMC as substrate after 24 hrs by fluorescence based assay	[PMID: 31855601]
Sf9	IC₅₀	>20000 nM Compound: LBH589	Inhibition of human N-terminal GST-tagged HDAC7 (518 to end residues) expressed in baculovirus infected Sf9 cells using Ac-Leu-Gly-Lys(Tfa)-AMC as susbtrate after 24 hrs by fluorescence based assay Inhibition of human N-terminal GST-tagged HDAC7 (518 to end residues) expressed in baculovirus infected Sf9 cells using Ac-Leu-Gly-Lys(Tfa)-AMC as susbtrate after 24 hrs by fluorescence based assay	[PMID: 31855601]
Sf9	IC₅₀	1.673 nM Compound: Pan; LBH589	Inhibition of recombinant human C-terminal GST/His-tagged HDAC3 (1 to 428 residues) co-expressed with human N-terminal GST-tagged NCOR2 (395 to 489 residues) in baculovirus infected Sf9 cells using Boc-Lys(acetyl)-AMC as substrate preincubated for 30 mins Inhibition of recombinant human C-terminal GST/His-tagged HDAC3 (1 to 428 residues) co-expressed with human N-terminal GST-tagged NCOR2 (395 to 489 residues) in baculovirus infected Sf9 cells using Boc-Lys(acetyl)-AMC as substrate preincubated for 30 mins	[PMID: 32321249]
Sf9	IC₅₀	1.926 nM Compound: Pan; LBH589	Inhibition of recombinant human C-terminal GST/His-tagged HDAC3 (1 to 428 residues) co-expressed with human N-terminal GST-tagged NCOR2 (395 to 489 residues) in baculovirus infected Sf9 cells using Boc-Lys(acetyl)-AMC as substrate preincubated for 10 mins Inhibition of recombinant human C-terminal GST/His-tagged HDAC3 (1 to 428 residues) co-expressed with human N-terminal GST-tagged NCOR2 (395 to 489 residues) in baculovirus infected Sf9 cells using Boc-Lys(acetyl)-AMC as substrate preincubated for 10 mins	[PMID: 32321249]
Sf9	IC₅₀	2.059 nM Compound: Pan; LBH589	Inhibition of recombinant human C-terminal GST/His-tagged HDAC3 (1 to 428 residues) co-expressed with human N-terminal GST-tagged NCOR2 (395 to 489 residues) in baculovirus infected Sf9 cells using Boc-Lys(acetyl)-AMC as substrate preincubated for 60 mins Inhibition of recombinant human C-terminal GST/His-tagged HDAC3 (1 to 428 residues) co-expressed with human N-terminal GST-tagged NCOR2 (395 to 489 residues) in baculovirus infected Sf9 cells using Boc-Lys(acetyl)-AMC as substrate preincubated for 60 mins	[PMID: 32321249]
Sf9	IC₅₀	2.097 nM Compound: Pan; LBH589	Inhibition of recombinant human C-terminal GST/His-tagged HDAC3 (1 to 428 residues) co-expressed with human N-terminal GST-tagged NCOR2 (395 to 489 residues) in baculovirus infected Sf9 cells using Boc-Lys(acetyl)-AMC as substrate preincubated for 90 mins Inhibition of recombinant human C-terminal GST/His-tagged HDAC3 (1 to 428 residues) co-expressed with human N-terminal GST-tagged NCOR2 (395 to 489 residues) in baculovirus infected Sf9 cells using Boc-Lys(acetyl)-AMC as substrate preincubated for 90 mins	[PMID: 32321249]
Sf9	IC₅₀	2.1 nM Compound: Pan; LBH589	Inhibition of recombinant human C-terminal GST/His-tagged HDAC3 (1 to 428 residues) co-expressed with human N-terminal GST-tagged NCOR2 (395 to 489 residues) in baculovirus infected Sf9 cells using Boc-Lys(acetyl)-AMC as substrate preincubated for 1 hr fo Inhibition of recombinant human C-terminal GST/His-tagged HDAC3 (1 to 428 residues) co-expressed with human N-terminal GST-tagged NCOR2 (395 to 489 residues) in baculovirus infected Sf9 cells using Boc-Lys(acetyl)-AMC as substrate preincubated for 1 hr fo	[PMID: 32321249]
T47D	IC₅₀	6.98 nM Compound: LBH589	Antiproliferative activity against human T47D cells assessed as reduction in cell growth after 72 hrs Antiproliferative activity against human T47D cells assessed as reduction in cell growth after 72 hrs	[PMID: 31855601]
THP-1	IC₅₀	0.001 μM Compound: Panobinostat	Antiproliferative activity against human THP-1 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human THP-1 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 37979441]

In Vitro

Panobinosta (LBH589) induces apoptosis of both MOLT-4 and Reh cells in a time- and dose-dependent manner. Panobinosta treatment results in histone (H3K9 and H4K8) hyperacetylation and regulation of cell-cycle control genes in Reh cells^[1]. Panobinostat exhibites potent antiproliferative activity in human NSCLC cell lines with the IC₅₀ ranging from 5 to 100 nM^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Panobinosta (10, 20 mg/kg, i.p.) significantly slows tumor growth derived from Meso and NSCLC cells in vivo models. Panobinosta markedly increases acetylation of histone H3 and H4 of H69 human SCLC cells harvest from SCID mice^[2]. Panobinostat (5, 10 and 20 mg/kg i.p.) demonstrates a clear benefit of decreased tumor burden, significantly improves TTE and reduces bone density loss in a disseminated multiple myeloma mouse model^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Essai clinique

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS No. 404950-80-7
Appearance Solid
Masse moléculaire 349.43
Formule C₂₁H₂₃N₃O₂
Color Off-white to light yellow
SMILES

O=C(/C=C/C1=CC=C(CNCCC2=C(NC3=C2C=CC=C3)C)C=C1)NO
Synonyms

LBH589; NVP-LBH589
Livraison

Room temperature in continental US; may vary elsewhere.

Stockage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	1 year
	-20°C	6 months

Publications (89)

All WB

Sort by:

Journal Impact Factor

Signal Transduct Target Ther

The noncanonical function of liver-type phosphofructokinase potentiates the efficacy of HDAC inhibitors in cancer. [Abstract]

2025 Oct 14;10(1):341. PMID: 41083431
Cancer Res

Targeting the SP/KLF Transcriptional Regulatory Network Synergizes with HDAC Inhibition to Impede Progression of H3K27M Diffuse Intrinsic Pontine Glioma. [Abstract]

2025 Jun 2;85(11):2100-2116. PMID: 40053472
Cancer Res

HAND2 assists MYCN enhancer invasion to regulate a noradrenergic neuroblastoma phenotype. [Abstract]

2023 Mar 2;83(5):686-699. PMID: 36598365
Cancer Res

PP2A Inhibitor PME-1 Drives Kinase Inhibitor Resistance in Glioma Cells. [Abstract]

2016 Dec 1;76(23):7001-7011. PMID: 27671680
Nat Commun

Epigenetic-based differentiation therapy for Acute Myeloid Leukemia. [Abstract]

2024 Jul 2;15(1):5570. PMID: 38956053
Nat Commun

Histone 4 lysine 5/12 acetylation enables developmental plasticity of Pristionchus mouth form. [Abstract]

2023 Apr 13;14(1):2095. PMID: 37055396
Hemasphere

Activating mutations remodel the chromatin accessibility landscape to drive distinct regulatory networks in KMT2A-rearranged acute leukemia. [Abstract]

2024 Sep 26;8(9):e70006. PMID: 39329074
Sci Transl Med

Differentiation of crescent-forming kidney progenitor cells into podocytes attenuates severe glomerulonephritis in mice. [Abstract]

2022 Aug 10;14(657):eabg3277. PMID: 35947676
Leukemia

Causal linkage of presence of mutant NPM1 to efficacy of novel therapeutic agents against AML cells with mutant NPM1. [Abstract]

2023 Jun;37(6):1336-1348. PMID: 36977823
J Exp Clin Cancer Res

A novel dual epigenetic approach targeting BET proteins and HDACs in Group 3 (MYC-driven) Medulloblastoma. [Abstract]

2022 Nov 11;41(1):321. PMID: 36357906

Panobinostat purchased from MedChemExpress. Usage Cited in: J Exp Clin Cancer Res. 2022 Nov 11;41(1):321. [Abstract]

The expression of BRD4 and MYC proteins are each downregulated by JQ1 (0.5 µM; 24 h) or panobinostat (PAN; 10 nM; 24 h) alone, and more profoundly by the combination of these two inhibitors in in MB HD-MB03 and D-283 cells.
J Nanobiotechnology

HDACi combination therapy with IDO1i remodels the tumor microenvironment and boosts antitumor efficacy in colorectal cancer with microsatellite stability. [Abstract]

2024 Dec 16;22(1):753. PMID: 39676171
Cell Rep Med

CAN-Scan: A multi-omic phenotype-driven precision oncology platform identifies prognostic biomarkers of therapy response for colorectal cancer. [Abstract]

2025 Apr 2:102053. PMID: 40187357
Clin Cancer Res

Epigenome Reprogramming Through H3K27 and H3K4 Trimethylation as a Resistance Mechanism to DNA Methylation Inhibition in BRAFV600E-Mutated Colorectal Cancer. [Abstract]

2024 Nov 15;30(22):5166-5179. PMID: 39269307
Cancer Lett

Subtype-specific HER3 enrichment in basal-like breast cancer is regulated via the GATA2/GATA3-FOXA1 axis. [Abstract]

2025 Sep 2:218001. PMID: 40907734
Cancer Lett

Intracellular AGR2 transduces PGE2 stimuli to promote epithelial-mesenchymal transition and metastasis of colorectal cancer. [Abstract]

2021 Oct 10:518:180-195. PMID: 34216690
Cell Death Dis

Phosphatase LHPP confers prostate cancer ferroptosis activation by modulating the AKT-SKP2-ACSL4 pathway. [Abstract]

2024 Sep 11;15(9):665. PMID: 39261475
Cell Death Dis

Global crotonylome reveals hypoxia-mediated lamin A crotonylation regulated by HDAC6 in liver cancer. [Abstract]

2022 Aug 17;13(8):717. PMID: 35977926
Acta Pharmacol Sin

Activation of unfolded protein response overcomes Ibrutinib resistance in diffuse large B-cell lymphoma. [Abstract]

2021 May;42(5):814-823. PMID: 32855532
NPJ Breast Cancer

Epigenetically upregulating TROP2 and SLFN11 enhances therapeutic efficacy of TROP2 antibody drug conjugate sacitizumab govitecan. [Abstract]

2023 Aug 11;9(1):66. PMID: 37567892
J Transl Med

Personalized medicine strategy for MPNSTs: using precision oncology on PDOX models to inform tumor boards. [Abstract]

2026 Feb 4;24(1):385. PMID: 41639724
Biomed Pharmacother

Histone deacetylase inhibitors enhance oncolytic herpes simplex virus therapy for malignant meningioma. [Abstract]

2022 Nov:155:113843. PMID: 36271587
Cell Rep

Decrypting lysine deacetylase inhibitor action and protein modifications by dose-resolved proteomics. [Abstract]

2024 May 24;43(6):114272. PMID: 38795348
J Med Chem

Systems Biology-Based Drug Repositioning Identifies Extracellular Matrix Module as a Therapeutic Target in Lung Squamous Cell Carcinoma. [Abstract]

2025 Oct 17. PMID: 41105954
J Med Chem

Discovery of a Novel Benzimidazole Derivative Targeting Histone Deacetylase to Induce Ferroptosis and Trigger Immunogenic Cell Death. [Abstract]

2024 Sep 12;67(17):15098-15117. PMID: 39145486
Anal Chem

Exploring the Potential of Chemically Matched Fragments as Internal Standards for Quantitative SERS with Panobinostat. [Abstract]

2025 Sep 2;97(34):18490-18498. PMID: 40839542
Mol Ther Nucleic Acids

2025 Dec 15.
JCI Insight

Methylation-induced suppression of YAP/TAZ confers sensitivity to HDAC inhibitors in high grade IDH mutant gliomas. [Abstract]

2025 Oct 9:e195385. PMID: 41066183
Cancer Cell Int

Construction of a prognostic model with histone modification-related genes and identification of potential drugs in pancreatic cancer. [Abstract]

2021 Jun 5;21(1):291. PMID: 34090418
Front Immunol

Synergistic Tumor Cytolysis by NK Cells in Combination With a Pan-HDAC Inhibitor, Panobinostat. [Abstract]

2021 Aug 31;12:701671. PMID: 34531855
Cells

HDAC Inhibition Induces Transient Phenotypic Inertia in Dormant OCCC Spheroids by Derepression of Cell Cycle Genes. [Abstract]

2026 Apr 10;15(8):673. PMID: 42041541
Cells

Inhibition of HDAC1/2 Along with TRAP1 Causes Synthetic Lethality in Glioblastoma Model Systems. [Abstract]

2020 Jul 10;9(7):1661. PMID: 32664214
Commun Biol

CBX4 enhances acute monocytic leukemia development via HDAC-mediated suppression of Runx1. [Abstract]

2026 Jun 1. PMID: 42225948
Commun Biol

LIFR inhibition enhances the therapeutic efficacy of HDAC inhibitors in triple negative breast cancer. [Abstract]

2021 Oct 29;4(1):1235. PMID: 34716410

Panobinostat purchased from MedChemExpress. Usage Cited in: Commun Biol. 2021 Oct 29;4(1):1235. [Abstract]

TNBC model cells (MDA-MB-231 and BT-549) were treated with indicated HDACi (Vorinostat: 10 µM; Panobinostat: 1 µM; Romidepsin: 1 µM; Givinostat: 1 µM) for 24 h and expression of LIFR, p-STAT3(Y705), and STAT3 were determined using Western blotting.
J Clin Endocrinol Metab

Targeting Corticotroph HDAC and PI3-Kinase in Cushing Disease. [Abstract]

2021 Jan 1;106(1):e232-e246. PMID: 33000123
Drug Des Devel Ther

Advances in the drug therapies of acute myeloid leukemia (except acute wpromyelocytic leukemia). [Abstract]

2018 Apr 30:12:1009-1017. PMID: 29750014
J Drug Deliv Sci Technol

Panobinostat-Loaded Albumin Nanoparticles for the Treatment of Pancreatic Cancer. [Abstract]

2025 Nov:113:107341. PMID: 40859982
Int J Mol Sci

Panobinostat Attenuates Experimental Autoimmune Encephalomyelitis in Mice via Suppressing Oxidative Stress-Related Neuroinflammation and Mitochondrial Dysfunction. [Abstract]

2024 Nov 9;25(22):12035. PMID: 39596104
Int J Oncol

Epigenetic inhibitors eliminate senescent melanoma BRAFV600E cells that survive long‑term BRAF inhibition. [Abstract]

2020 Jun;56(6):1429-1441. PMID: 32236593
PLoS Pathog

Chromatin remodeling controls Kaposi's sarcoma-associated herpesvirus reactivation from latency. [Abstract]

2018 Sep 13;14(9):e1007267. PMID: 30212584

Panobinostat purchased from MedChemExpress. Usage Cited in: PLoS Pathog. 2018 Sep 13;14(9):e1007267. [Abstract]

Immunoblot analysis for vIL-6, ORF45, or actin is performed on lysates from BCBL-1 cells treated with NaB+TPA, Romidepsin or Panobinostat.
Pharmaceuticals (Basel)

Valproic Acid Prodrug Affects Selective Markers, Augments Doxorubicin Anticancer Activity and Attenuates Its Toxicity in a Murine Model of Aggressive Breast Cancer. [Abstract]

2021 Nov 30;14(12):1244. PMID: 34959644
Int Immunopharmacol

Panobinostat suppresses cGAS-STING pathway activation and ameliorates DSS-induced colitis in mice. [Abstract]

2025 Oct 10:167:115637. PMID: 41075748
Eur J Pharmacol

Anti-leukemic effects of histone deacetylase (HDAC) inhibition in acute lymphoblastic leukemia (ALL) cells: Shedding light on mitigating effects of NF-κB and autophagy on panobinostat cytotoxicity. [Abstract]

2020 May 15;875:173050. PMID: 32142770
Rheumatology (Oxford)

Autophagy inhibitors block pathogenic NET release in immune-mediated inflammatory disease without impairing host defence. [Abstract]

2025 Aug 13:keaf437. PMID: 40802538
Neurooncol Adv

Histone deacetylase inhibitors enhance estrogen receptor beta expression and augment agonist-mediated tumor suppression in glioblastoma. [Abstract]

2021 Jul 17;3(1):vdab099. PMID: 34485908
Sci Rep

A novel human acute myeloid leukemia cell line SDEY-AML1 with KMT2A: MLLT3, IKZF1: EVX1 fusions exhibits high tumorigenicity in NSG mice. [Abstract]

2026 Feb 8;16(1):7792. PMID: 41656387
Biomedicines

An Orthotopic Model of Uveal Melanoma in Zebrafish Embryo: A Novel Platform for Drug Evaluation. [Abstract]

2021 Dec 10;9(12):1873. PMID: 34944689
J Virol

Development of a Novel In Vitro Primary Human Monocyte-Derived Macrophage Model To Study Reactivation of HIV-1 Transcription. [Abstract]

2021 Sep 9;95(19):e0022721. PMID: 34287050
Bioengineering (Basel)

Precision Oncology for High-Grade Gliomas: A Tumor Organoid Model for Adjuvant Treatment Selection. [Abstract]

2025 Oct 19;12(10):1121. PMID: 41155119
Int J Parasitol Drugs Drug Resist

2026 May 17;31:100649.
Cancer Res Commun

Histone Deacetylase Inhibitors Target DNA Replication Regulators and Replication Stress in Ewing Sarcoma Cells. [Abstract]

2025 Jun 1;5(6):1034-1048. PMID: 40478628
Cancer Res Commun

Activator Protein-1 (AP-1) Signaling Inhibits the Growth of Ewing Sarcoma Cells in Response to DNA Replication Stress. [Abstract]

2023 Aug 17;3(8):1580-1593. PMID: 37599787
Cancer Med

Synergistic Antitumor Activity of HAT Inhibitor A485 and XPO1 Inhibitor KPT8602 in Multiple Myeloma. [Abstract]

2026 Jun;15(6):e71985. PMID: 42231094
Hum Cell

Panobinostat inhibits breast cancer progression via Vps34-mediated exosomal pathway. [Abstract]

2023 Jan;36(1):366-376. PMID: 36329365
Cell Biol Int

Abrogation of histone deacetylases (HDACs) decreases survival of chronic myeloid leukemia cells: New insight into attenuating effects of the PI3K/c-Myc axis on panobinostat cytotoxicity. [Abstract]

2021 May;45(5):1111-1121. PMID: 33501756
Mol Immunol

Role of HDAC6-STAT3 in immunomodulatory pathways in Colorectal cancer cells. [Abstract]

2023 Dec:164:98-111. PMID: 37992541
Insects

BmCBP Catalyzes the Acetylation of BmApoLp-II Protein and Regulates Its Stability in Silkworm, Bombyx mori. [Abstract]

2023 Mar 23;14(4):309. PMID: 37103124
J Appl Toxicol

Inorganic arsenic exposure promotes malignant progression by HDAC6-mediated down-regulation of HTRA1. [Abstract]

2023 Aug;43(8):1214-1224. PMID: 36861143
Neuroscience

Treatment with Non-specific HDAC Inhibitors Administered after Disease Onset does not Delay Evolution in a Mouse Model of Progressive Multiple Sclerosis. [Abstract]

2021 Jun 15:465:38-45. PMID: 33862148
Int J Biochem Cell Biol

Pan-HDAC inhibitor panobinostat, as a single agent or in combination with PI3K inhibitor, induces apoptosis in APL cells: An emerging approach to overcome MSC-induced resistance. [Abstract]

2020 May;122:105734. PMID: 32119989
BMC Pharmacol Toxicol

Panobinostat (LBH589) combined with AM1241 induces cervical cancer cell apoptosis through autophagy pathway. [Abstract]

2023 Sep 22;24(1):45. PMID: 37740231
PLoS One

Chorioallantoic membrane (CAM) assay to study treatment effects in diffuse intrinsic pontine glioma. [Abstract]

2022 Feb 14;17(2):e0263822. PMID: 35157705
Gene

Panobinostat reverses HepaCAM gene expression and suppresses proliferation by increasing histone acetylation in prostate cancer. [Abstract]

2022 Jan 15:808:145977. PMID: 34592353
J Recept Signal Transduct Res

Synergistic effects of BKM120 and panobinostat on pre-B acute lymphoblastic cells: an emerging perspective for the simultaneous inhibition of PI3K and HDACs. [Abstract]

2022 Feb;42(1):100-108. PMID: 33969806
Insect Mol Biol

The effect of acetylation on the protein stability of BmApoLp-III in the silkworm, Bombyx mori. [Abstract]

2020 Feb;29(1):104-111. PMID: 31390480
Arch Insect Biochem Physiol

The acetylation modification regulates the stability of Bm30K-15 protein and its mechanism in silkworm, Bombyx mori. [Abstract]

2021 Jul;107(3):e21823. PMID: 34075635
Proteome Sci

iTRAQ-based proteomic study on monocyte cell model discovered an association of LAMP2 downregulation with HIV-1 latency. [Abstract]

2024 May 15;22(1):6. PMID: 38750478
bioRxiv

Spatially-Resolved Multiomic Atlas of Leiomyosarcoma Identifies Two Clinically Relevant Epigenetically-Driven Cell States. [Abstract]

2026 May 26:2026.05.22.726988. PMID: 42244620
bioRxiv

Radiation synergizes with BET inhibition to stimulate durable, systemic anti-tumor immunity in murine cancer models. [Abstract]

2026 Feb 18:2026.02.16.706212. PMID: 41757027
Charles University

2026.
University of Gottingen

2026.
Uppsala University

2025.
Patent

US20250152731A1.
Patent

US20250161243A1.
bioRxiv

2025 January 15.
Patent

US20240344035A1
Patent

US20240344035A1.
The Ohio State University

2024 May.
SSRN

2023 Sep 29.
Research Square Preprint

2023 Aug 14.
University of Gothenburg

2023 Jun 27.
bioRxiv

2023 Jun 5.
bioRxiv

2023 Apr 14.
Uppsala University

2022 Feb.
Research Square Preprint

2021 Dec.
Universitat Politècnica de València

2020 Sep.
Albert-ludwigs-university Of Freiburg

2019 Dec.
bioRxiv

2019 Nov.
Patent

US20180263995A1.
China Biotechnology

2016, 36(6): 9-17.

Panobinostat purchased from MedChemExpress. Usage Cited in: China Biotechnology. 2016, 36(6): 9-17.

The HDAC expression of PC3 cell with different concentration of Panobinostat. (a) HDACs mRNA expression is analyzed by real time PCR (b) HDACs protein expression is analyzed by Western blot.

Solvant et solubilité

In Vitro:

DMSO : ≥ 100 mg/mL (286.18 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.8618 mL

14.3090 mL

28.6180 mL

5 mM

0.5724 mL

2.8618 mL

5.7236 mL

10 mM

0.2862 mL

1.4309 mL

2.8618 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Calculateur de molarité

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculateur de dilution

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (7.15 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (7.15 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (7.15 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

Protocol 4

Add each solvent one by one: 5% DMSO 40% PEG300 5% Tween-80 50% Saline

Solubility: ≥ 2.5 mg/mL (7.15 mM); Clear solution

Protocol 5

Add each solvent one by one: 5% DMSO 95% (20% SBE-β-CD in Saline)

Solubility: 2.5 mg/mL (7.15 mM); Suspended solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Protocole

Cell Assay^[1]

Cells are washed with ice-cold PBS containing 0.1 mM sodium orthovanadate, and total proteins are isolated using RIPA lysis buffer, which includes protease inhibitors (leupeptin, antipain, and aprotinin), 0.5 mM PMSF, and 0.2 mM sodium orthovanadate. Protein amounts are quantified using the Bio-Rad protein assay. Equal amounts of proteins are loaded onto an sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) gel, transferred onto nitrocellulose membrane, and probed with the antibody of interest: mouse monoclonal c-Myc and mouse monoclonal p21 antibodies; rabbit polyclonal phospho-Histone H2A.X, rabbit polyclonal acetyl-Histone H3 (Lys9), and rabbit polyclonal acetyl-Histone H4 (Lys8) antibodies; mouse monoclonal p27/KIP1 antibody; mouse monoclonal anti-β-actin; and mouse monoclonal anti-GADD45G. Membranes are then washed, reprobed with appropriate horseradish peroxidase-conjugated secondary antibodies, and developed with SuperSignal chemiluminescent substrate.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration^[1]

AE17 and TC-1 cancer cells (1×10⁶ cells) are injected into the flanks of adult female C57Bl/6 mice and severe combined immunodeficiency (SCID) mice. M30 (10×10⁶ cells), A549 (5×10⁶ cells), H69 (2.5×10⁶ cells), BK-T (6.5×10⁶), H526 (10×10⁶), and RG1 (10×10⁶) cells are also injected, but in the presence of matrigel, into the flanks of SCID mice. When tumors reach 100 to 500 mm³, panobinostat is administered via i.p. injections (10-20 mg/kg) on a daily schedule (5-days-on, 2-days-off regimen) for the entire duration of the experiment. Control micereceive i.p. injections with dextrose 5% in water. Every tumor is measured with a caliper at least twice weekly. For evaluation of the effects of combination therapy on SCLC-derived tumors, SCID mice with H69 tumors are administered panobinostat. Three days after the initiation of panobinostat, and again 1 wk later, etoposide (40 mg/kg) is administered i.p.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Pureté et documentation

Select Batch:

Pureté: 99.98%

Assay: 99.98%

ee.: 99.98%

Fiche technique (280 KB)
SDS (805 KB)
- English - EN (805 KB)
- Français - FR (805 KB)
- Deutsch - DE (805 KB)
- Norwegian - NO (805 KB)
- Español - ES (805 KB)
- Swedish - SV (805 KB)
- Italian - IT (805 KB)
- Korean - KR (805 KB)
- Portuguese - PT (805 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Instruction de manipulation (2659 KB)

Références

[1]. Scuto A, et al. The novel histone deacetylase inhibitor, LBH589, induces expression of DNA damage response genes and apoptosis in Ph- acute lymphoblastic leukemia cells. Blood. 2008 May 15;111(10):5093-100. [Content Brief]

[2]. Crisanti MC, et al. The HDAC inhibitor panobinostat (LBH589) inhibits mesothelioma and lung cancer cells in vitro and in vivo with particular efficacy for small cell lung cancer. Mol Cancer Ther. 2009 Aug;8(8):2221-31. [Content Brief]

[3]. Ocio EM, et al. In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma. Haematologica. 2010 May;95(5):794-803. [Content Brief]

[4]. Barton K, et al. Broad activation of latent HIV-1 in vivo. Nat Commun. 2016;7:12731. Published 2016 Sep 8. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.8618 mL	14.3090 mL	28.6180 mL	71.5451 mL
	5 mM	0.5724 mL	2.8618 mL	5.7236 mL	14.3090 mL
	10 mM	0.2862 mL	1.4309 mL	2.8618 mL	7.1545 mL
	15 mM	0.1908 mL	0.9539 mL	1.9079 mL	4.7697 mL
	20 mM	0.1431 mL	0.7155 mL	1.4309 mL	3.5773 mL
	25 mM	0.1145 mL	0.5724 mL	1.1447 mL	2.8618 mL
	30 mM	0.0954 mL	0.4770 mL	0.9539 mL	2.3848 mL
	40 mM	0.0715 mL	0.3577 mL	0.7155 mL	1.7886 mL
	50 mM	0.0572 mL	0.2862 mL	0.5724 mL	1.4309 mL
	60 mM	0.0477 mL	0.2385 mL	0.4770 mL	1.1924 mL
	80 mM	0.0358 mL	0.1789 mL	0.3577 mL	0.8943 mL
	100 mM	0.0286 mL	0.1431 mL	0.2862 mL	0.7155 mL

Keywords

Panobinostat

89 Cited Publications

100 mg Obtenir un devis

Subscribe to the

MedChemExpress

Newsletter

Nom du produit:
Cat. No.:
Quantité:
MCE Japan Authorized Agent:

Nom du produit:
CAS No.:
Species:
Pureté:
Quantité:

Panobinostat

Anti-Infection Compound Library

Apoptosis Compound Library

Cell Cycle/DNA Damage Compound Library

Epigenetics Compound Library

FDA-Approved Drug Library

Histone Modification Research Compound Library

Anti-Cancer Compound Library

Autophagy Compound Library

Anti-Aging Compound Library

Drug Repurposing Compound Library

Covalent Screening Library

Reprogramming Compound Library

Oxygen Sensing Compound Library

Anti-COVID-19 Compound Library

Orally Active Compound Library

FDA Approved & Pharmacopeial Drug Library

Anti-Breast Cancer Compound Library

Anti-Lung Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Targeted Therapy Drug Library

Anti-Liver Cancer Compound Library

Rare Diseases Drug Library

Chemotherapy Drug Library

EMA-Approved Drug Library

FDA-Approved Anticancer Drug Library

Anti-Prostate Cancer Compound Library

Anti-Pulmonary Fibrosis Compound Library

Osteogenesis Compound Library

Off-patent Drug Library

Highly Selective Inhibitors Library

Highly Selective Activators Library

Cell Death Library

Anti-Hematopathy Compound Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Covalent Screening Library Plus

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

Anti-Brain Cancer Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

Anti-Cancer Approved Drug Library

Cardiotoxic Compound Library

High-Efficiency Gene Editing Compound Library

RNA Binding Bioactive Compound Library

Lactylation Compound Library

Publications Citing Use of MedChemExpress (MCE) Panobinostat

Voir tous les produits spécifiques à Isoform HDAC

Voir tous les produits spécifiques à Isoform HIV

Activité biologique

Chemical Information

Publications (89)

Solvant et solubilité

Protocole

Pureté et documentation

Références

Help & FAQs

Complete Stock Solution Preparation Table

Panobinostat Related Classifications

HY-10224 Related Classifications